GlassScriptPhysician profile
Seema Y Haque
NPI 1396784914
$5,985.04
in general payments reported to CMS, 2019-2025
29 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,353 · 2020: $1,267 · 2021: $1,436 · 2022: $842 · 2023: $628 · 2024: $168 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,038.04 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $912.57 | 2019-2020 | |
| Abbvie INC. | $784.97 | 2021-2023 | |
| Alkermes, INC. | $692.80 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $542.02 | 2020-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $482.43 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $479.95 | 2019-2025 | Abilify Mycite, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $349.85 | 2019-2022 | |
| Adlon Therapeutics L.P. | $214.67 | 2020-2021 | |
| Shire North American Group INC | $205.53 | 2019 | |
| Ironshore Pharmaceuticals INC. | $172.53 | 2019-2023 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $114.83 | 2019-2021 | |
| Almatica Pharma LLC | $111.75 | 2021-2023 | Loreev Xr |
| Tris Pharma INC | $103.23 | 2019-2023 | Dyanavel Xr |
| Eisai INC. | $100.47 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $96.47 | 2021-2023 | Qelbree |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $94.72 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $89.20 | 2023-2025 | Quviviq, Quviviq |
| Lundbeck LLC | $85.26 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $66.81 | 2019 | |
| Axsome Therapeutics, INC. | $48.11 | 2023-2024 | Auvelity |
| Merck Sharp & Dohme LLC | $40.17 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $39.35 | 2019-2020 | |
| Bausch Health US, LLC | $35.10 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $32.49 | 2022 | |
| Noven Therapeutics, LLC | $22.39 | 2020 | |
| Neurocrine Biosciences, INC. | $20.56 | 2019 | |
| Ge Healthcare | $17.45 | 2023 | |
| Neos Therapeutics, LP | $15.67 | 2020 | |
| Soleno Therapeutics, INC. | $13.69 | 2025 | Vykat Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Haque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.